You are herePharma News
(2nd September, 2014); Wockhardt Ltd’s New Drug Discovery program in Anti - Infective research received a major boost after two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from the US FDA. This is the first instance of an Indian Pharmaceutical company receiving a QIDP status.
Extensive experience in clinical practice and expanding research programme support use of Pradaxa® for clot prevention
(2nd September, 2014; Business Wire India); Five years on from the first breakthrough presentation of the pivotal RE-LY® clinical trial of Pradaxa® (dabigatran etexilate) for the prevention of stroke in non-valvular atrial fibrillation (NVAF), extensive clinical trial and real-world data support Pradaxa® in various indications. Boehringer Ingelheim continues to grow the evidence base for Pradaxa® to improve care for patients at risk of blood clots and today announces the initiation of Phase III of the GLORIA™-AF registry program in North America and in Europe. During this final phase of the registry program, data on the overall safety and effectiveness of antithrombotic treatments will be collected.
Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate
(22nd August, 2014; Business Wire India); Celgene Corporation (NASDAQ:CELG) announced that results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell lymphoma (DLBCL) were published online ahead of print in the Journal of Clinical Oncology.
(22nd August, 2014); Due to effective vaccination, polio is comletely eradiated from India and World Health Organisation (WHO) presented official certification to India for its ‘Polio Free’ status in March 2014. But it seems like polio itself doesn't want to give up and wants to extend its victims. Researchers alaraming findings notified mutated poliovirus that can resist vaccine protection to a considerable extent was found in victims of an outbreak in the Congo in 2010. The pathogen could also potentially have infected many people in Germany. The results appear now in the magazine PNAS.
(13th August, 2014); Dr Harsh Vardhan, Minister for Health, has clarified that India does not have any confirmed or even suspected Ebola virus affected person. World Health Organization (WHO) had informed that one Indian passenger had travelled on the same flight in which Ebola virus patient (foreign national) was travelling from Monrovia to Lagos. This Indian passenger is back in India. He has been tracked and his health is being regularly monitored. The Health Minister said “We are happy to share that the said person is healthy, fit and fine.”
(6th August, 2014); Sanofi in India announced today that it has entered into a marketing and distribution agreement with Emcure Pharmaceuticals (Emcure) for its oncology portfolio in India. As per the agreement, while Sanofi will continue to own its oncology range - comprising 4 brands namely Taxotere®, Jevtana®, Fludara® and Fasturtec®, Emcure will market and distribute these brands through its Specialty Unit.
(6th August, 2014); Roche announced on last Monday that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark. Santaris Pharma has pioneered its proprietary Locked Nucleic Acid (LNA) platform that has contributed to an emerging era of RNA-targeting therapeutics. This new class of medicines has the potential to address difficult to treat diseases in a range of therapeutic areas.